arthritis cardiac arrhythmia epilepsy and brain tumors c o v anc e 1999 annual r epor t influenza a b diabetes data into medicines transforming consolidated statements of income year ended december 31 1998 1997 1996 1995 net revenues 828 980 731 574 590 651 494 409 174 from operations 99 547 1 91 879 77 660 65 265 52 177 operating margin 12 0 6 13 2 8 53 599 48 608 39 754 32 441 26 996 basic earnings per share 84 69 57 n diluted 83 weighted average shares 58 477 199 050 114 254 042 063 644 680 794 774 334 463 587 distribution us rest world geographically 67 late stage development services 33 early by segment service area biomanufacturing commercialization 21 clinical support
